Protocol
Tirzepatide (10mg Vial)
Complete dosage protocol and reconstitution guide for Tirzepatide (10mg Vial).
Calculator preset
Run the vial math before tracking.
At 5 mg/mL, 1 mg = 0.20 mL = 20 units on a U-100 insulin syringe.
01 · At a glance
Quickstart Highlights
Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite [1] [2] . Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing [1] . Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists [3] [4] .
02 · Dosing & reconstitution
Dosing & Reconstitution Guide
A practical calculator-ready setup based on the imported protocol reference. Use these values as a math starting point, then verify every entry against your own vial, diluent, and professional guidance.
Standard / Gradual Approach (2 mL = 5.0 mg/mL)
2.5–15 mg once weekly (gradual 4‑week titration steps).
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.
- Use within 28 days of reconstitution [6] .
03 · What you'll need
Supplies Needed
Keep this as a planning checklist. TNHL does not sell or verify supplies on this page, and no supplier quality claims are made here.
- 12 weeks (2.5→7.5 mg/wk): ~60 mg total ≈ 6 vials
- 16 weeks (2.5→10 mg/wk): ~100 mg total ≈ 10 vials
- 12 weeks: 16 syringes (~1.3/week avg)
- 16 weeks: 24 syringes (~1.5/week avg)
- 8 weeks (3 vials): 6 mL → 1 × 10 mL bottle
- 12 weeks (6 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (10 vials): 20 mL → 2 × 10 mL bottles
- Per week: 2 swabs (1 injection day)
- 8 weeks: 16 swabs → recommend 1 × 100‑count box
- 12 weeks: 24 swabs → recommend 1 × 100‑count box
- 16 weeks: 32 swabs → recommend 1 × 100‑count box
Protocol Overview
- Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation [2] .
- Schedule: Weekly subcutaneous injection on the same day each week for 12–16+ weeks.
- Dose Range: 2.5–15 mg weekly with 4‑week titration intervals.
- Reconstitution: 2.0 mL per 10 mg vial (5.0 mg/mL) for manageable injection volumes.
- Storage: Lyophilized frozen; reconstituted refrigerated for up to 28 days.
Dosing Protocol
- Suggested weekly titration approach.
- Start: 2.5 mg once weekly for 4 weeks (initiation dose) [1] .
- Escalate: Increase by 2.5 mg every 4 weeks as tolerated.
- Maintenance: 5–15 mg weekly based on response and tolerability.
- Frequency: Once per week (subcutaneous), same day each week.
- Timing: Any time of day; with or without food; rotate injection sites.
Storage Instructions
- Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution [6] .
- Shelf life: Use reconstituted solution within 28 days [6] .
- Allow vials to reach room temperature before opening to reduce condensation uptake.
04 · Good to know
Important Notes
- Complementary strategies for best outcomes.
- Pair with a balanced, calorie‑appropriate diet; reduced appetite may naturally decrease intake.
- Prioritize protein to preserve lean mass during weight loss.
- Combine resistance training and aerobic activity to support metabolic health.
- Stay hydrated, especially given potential gastrointestinal effects.
- Prioritize sleep and stress management to support adherence and recovery.
05 · How it works
How This Works
Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite [1] [2] .
Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing [1] .
Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists [3] [4] .
The library page pairs that educational context with calculator-ready vial math, so users can understand the protocol structure and then track their own entered values in one place.
06 · Daily habits
Lifestyle Factors
- Keep meals, training, sleep, and recovery notes in the journal so trends are easier to review.
- Track body metrics only if they are relevant to the user's goal and approved data sources.
- Use consistent timing and logging habits so adherence data is meaningful.
07 · What to expect
Potential Benefits & Side Effects
- Tirzepatide observations should be recorded conservatively: expected research endpoints, tolerability notes, injection-site reactions when applicable, sleep, appetite, energy, mood, and any adverse or unusual response.
- This section is not a claim of therapeutic benefit.
08 · Technique
Injection Technique
- Wash hands with soap and water.
- Wipe the vial stopper and chosen site with alcohol, then let both dry.
- Confirm the vial concentration, calculator result, and intended draw amount before loading the syringe.
- Use the route and needle technique directed by a qualified professional or product instructions.
- For subcutaneous injections, rotate sites and inject slowly to limit leakage and irritation.
- Do not reuse needles or syringes.
- Dispose of sharps in a puncture-resistant container.
- Return stored items promptly to the correct temperature.
- Log dose, site, date, time, inventory change, and any observation.
09 · Evidence
References
Related pages